Program
BET Inhibitor JAB-8263
Its studies are mostly in Arthritis, Rheumatoid · Ovarian Neoplasms, led by Jacobio Pharmaceuticals.
Furthest: phase 2, since Dec 23, 20203 company-led studies, 2 open or runningNext primary completion: Jun 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jacobio Pharmaceuticals | 32 open or running | phase 2since Dec 23, 2020 | Oct 9, 2020 | Jun 30, 2027phase 2 · NCT07684157 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 9, 2020First study: phase 1 study in Solid Tumors, AdultFirst studyNCT04587479 · 41 enrolled · United States
- Dec 23, 2020Phase 2 study in Ovarian NeoplasmsNCT04686682 · 152 planned · China
- Jun 29, 2026Phase 2 study in Arthritis, RheumatoidNCT07684157 · 32 planned · China
Ahead
- Jun 30, 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT07684157
- Jan 2028Primary completion: phase 2 study in Ovarian NeoplasmsNCT04686682
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07684157Arthritis, Rheumatoid · China | 2 | Recruiting | Jun 30, 2027 | 32 |
| NCT04686682Ovarian Neoplasms · China | 2 | Recruiting | Jan 2028 | 152 |
| NCT04587479Solid Tumors, Adult · United States | 1 | Completed | Oct 31, 2024 | 41 |
How it is read
Names in the registry
- “JAB-8263”, 5 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 1 study
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.